What the FDA said about compounded peptides

The FDA said two different things in 2026, and they come from two different parts of the agency. Its staff reviewers said the evidence was too thin to judge safety or efficacy. Its advisory committee then voted, narrowly, to let US compounding pharmacies use six of the peptides anyway.

The staff position is the older one. From 29 September 2023, BPC-157 sat in 503A Category 2 with this summary: compounded BPC-157 "may pose risk for immunogenicity for certain routes of administration", and the FDA "lacks sufficient information to know whether the drug would cause harm" in humans. ^[3] The entry for the TB-500 fragment (LKKTETQ) says the FDA had not identified any human exposure data at all. ^[3]

That view did not change before the July meeting. Science reported that FDA scientists said, in their dossiers for the committee, that there was too little evidence to conclude any of the peptides was either safe or effective, and that they carried a high risk of triggering an immune overreaction. ^[4]

The committee's view is the newer one, and it is advice. The FDA's own meeting page says advisory committees make non-binding recommendations, which the agency generally follows but is not legally bound to follow. ^[8]

An Internet Archive copy of the FDA's Category 2 page, captured on 5 March 2026, shows 26 entries. BPC-157, emideltide, Epitalon, KPV, MOTS-c, Semax and the TB-500 fragment are all listed as 503A Category 2 substances, each with the date 29 September 2023. ^[3] That 2023 listing was the FDA position in force at the start of 2026, and every step below came after it.

Five dated steps moved these peptides from a US safety-risk list to an advisory vote. None of them is an approval.

Science reported that HHS Secretary Robert F. Kennedy Jr. said the April move would "immediately begin shifting demand away from the black market". ^[4] The FDA's April notice gives a narrower, procedural reason: the nominations were withdrawn by the nominators, and the agency would consult the committee instead. ^[1]

Five other substances from the same notice, cathelicidin LL-37, dihexa acetate, GHK-Cu, PEG-MGF and melanotan II, were scheduled for committee review before the end of February 2027. ^[1] Kisspeptin-10 stayed in 503A Category 2. ^[9]

The committee voted on seven peptides, each for one or more specific uses the FDA had reviewed. BPC-157 was reviewed for ulcerative colitis, KPV and TB-500 for wounds, MOTS-c for obesity and osteoporosis, emideltide for opioid withdrawal, chronic insomnia and narcolepsy, Semax for cerebral ischaemia, migraine and trigeminal neuralgia, and Epitalon for insomnia. ^[5]

Uses come from the Federal Register notice ^[5] and results from the BMJ's report, which says every recommendation passed by a narrow majority. ^[2]

Two details matter when you read the headlines. Science reported that the committee included at least seven people involved in companies selling peptides. ^[4] And the BMJ noted that the newly appointed committee had faced criticism over conflicts of interest. ^[2]

It concerns which raw ingredients a licensed US pharmacist or physician may use to compound a drug for a patient. Section 503A lets compounders use a bulk substance that has a USP monograph, that is a component of an FDA-approved drug, or that appears on a list the Secretary develops "through regulations". ^[5] That third route is the 503A Bulks List.

So a committee vote is one step in a rulemaking process. We searched the Federal Register on 29 September 2026 for FDA documents mentioning 503A published since 1 April 2026. It returned seven notices, including the April meeting notice, and no proposed or final rule. ^[6] Science reported that the FDA said it would issue a final decision after the meeting. ^[4] We found no published rule by our check date.

The same FDA review process ran in the other direction for some peptides. A 1 May 2026 notice proposed leaving semaglutide, tirzepatide and liraglutide off the separate 503B list used by outsourcing facilities. ^[10]

The FDA approves specific drug products, and several peptide medicines hold that approval. Science notes that the GLP-1 peptide drugs used for diabetes and obesity went through clinical tests in many thousands of people, which the seven reviewed peptides did not. ^[4]

BPC-157 has no FDA approval. A 2025 literature and patent review states that it "has not been approved for use in standard medicine by the FDA and other global regulatory authorities" (PMID 40005999). ^[11] None of the seven peptides the committee reviewed is an approved drug, and a place on the 503A Bulks List would not make any of them one.

The research on both is mostly preclinical, and the human evidence is thin. That is the same gap the FDA's reviewers described.

For BPC-157:

• A 2019 review in Cell and Tissue Research found that the majority of studies used small rodent models, that its efficacy "is yet to be confirmed in humans", and that only a handful of research groups had studied it in depth (PMID 30915550). ^[12]
• A 2025 systematic review screened 544 articles from 1993 to 2024 and included 36 studies: 35 preclinical and 1 clinical. It found no clinical safety data (PMID 40756949). ^[13]
• A 2025 pilot study at a private clinic in Florida gave intravenous BPC-157 to 2 participants and reported no measurable effects on the heart, liver, kidney, thyroid and glucose markers it tested (PMID 40131143). ^[14] Two people cannot establish safety.

For TB-500, the first question is identity. A 2012 anti-doping study identified the N-acetylated 17-23 fragment of thymosin beta-4 (Ac-LKKTETQ) in a product sold as TB-500 (PMID 22962027). ^[15] The FDA's 2023 entry for that fragment recorded no human exposure data. ^[3] Our TB-500 explainer separates the fragment from the full protein, and the BPC-157 explainer covers the rodent literature in detail.

No. The FDA regulates US products and US pharmacies. Australian status comes from the Poisons Standard, State and Territory law, and the TGA.

Under the June 2026 Poisons Standard (F2026L00633, in force from 1 June 2026), BPC-157 and TB-500 are both Schedule 4 (prescription only) and both listed in Appendix D clause 5, which makes possession without authority an offence. ^[7] A vote in Maryland does not amend that instrument.

The TGA's position ran the other way through 2026. Its April 2026 safety alert names BPC-157 and TB-500 among its examples of unapproved peptide products and says a "research use only" disclaimer does not make supply lawful. ^[16] It says peptide products regulated as therapeutic goods must be on the Australian Register of Therapeutic Goods before they can be imported or supplied, with limited exceptions. ^[17] In May it warned that code-only or poorly labelled vials will not be released under the Personal Importation Scheme, ^[18] and in June it added unapproved peptide products to its priority compliance areas. ^[19]

In sport, the 2026 WADA Prohibited List names BPC-157 in class S0 and TB-500 in class S2, both prohibited at all times. ^[20] Our guide to Australian peptide law and the Poisons Standard sets out the schedule for every compound we stock.

Read the batch certificate. None of the FDA's 2026 steps says anything about the contents of a particular vial, and neither does the Poisons Standard.

At Peptides Collective, every batch is tested by an independent lab before it goes on sale, for purity by HPLC and identity by mass spectrometry. The certificate is published under the batch number printed on the vial, and you can search it in the certificate of analysis library. The BPC-157 5mg product page and the TB-500 10mg product page each link the certificate for the current batch.

For BPC-157, the identity result should correspond to the PubChem molar mass of 1419.5 g/mol for the 15-residue sequence GEPPPGKPADDAGLV. For TB-500 (Ac-LKKTETQ), PubChem lists 889.0 g/mol. Our guide on how to read a peptide certificate of analysis explains the trace, the spectrum and net peptide content.

The FDA has approved none of the popular research peptides. Its reviewers said in 2023, and again in 2026, that the evidence was too thin to judge them, while its advisory committee narrowly recommended six for US compounding in July 2026, a non-binding step with no rule published by 29 September 2026. For Australian researchers the governing facts are local: BPC-157 and TB-500 are Schedule 4 with a possession offence, and the TGA classes them as unapproved. A batch certificate is the only document that tells you what is in a vial.